National Cancer Institute 5U19CA264385-05

6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification

The award supports preclinical research on 6-thio-2'-deoxyguanosine as a novel therapeutic agent for glioblastoma, focusing on efficacy, biomarkers, and safety to enable clinical trials.

Description

This project focuses on the use of 6-thio-2'-deoxyguanosine (6-thio-dG), a purine analog pro-drug that induces telomerase-mediated cytotoxic DNA damage at telomeres, as a potential therapy for glioblastoma (GBM). The project aims to characterize the pre-clinical efficacy and biomarkers of 6-thio-dG alone or with Temozolomide (TMZ) in patient-derived models, test anti-tumor efficacy and inflammatory potential in murine models, and define cell toxicity and inflammatory potential in ex vivo glioma tissue and organoids. The goal is to inform clinical trial design and advance 6-thio-dG toward clinical application in GBM.

View original record